James Sabry on industry-shaping changes in innovation and deal-making
Business development veteran talks to BioCentury as he transitions from Roche to BioMarin, entering the one biotech segment he’s not yet been in
James Sabry is emerging from a longer stint at Genentech and Roche than he anticipated walking in, and now is embarking on the next phase of his storied career as Chief Business Officer at BioMarin. With a 360 degree view of the industry, he discusses with BioCentury some of the industry-shaping changes he sees in both innovation and deal-making, and why he thinks they’re here to stay.
Sabry’s 14 years at Roche (SIX:ROG; OTCQB:RHHBY) gave him deep expertise in deal-making from the pharma side of the table, serving for the last six years as EVP and global head of partnering, and for the eight years before that as SVP of Genentech partnering. He sat the other side of the table in smaller biotechs earlier in his career, first as founder, president and CEO of Cytokinetics Inc. (NASDAQ:CYTK), and then for two years as president and CEO of Arete Therapeutics. ...